Prosecution Insights
Prosecution Insights
Tech Center 2600 • Art Units: 1600 1631 1671 1685 2156 2687
This examiner grants 70% of resolved cases
Within Tech Center 2600 and Art Unit 1600, Examiner Jesse P Frumkin has handled 269 resolved cases. The allowance rate for these cases is 69.9 percent. This figure serves as a reference for the likelihood of success. A median days to allowance of 1324 defines the prosecution timeline. This duration is a consideration for applicants when managing their portfolios.
Data shows an interview lift of 48.7 percent. With 269 resolved cases, this lift indicates the impact of communication on results. The 1324 days to allowance provides a standard for pendency. The 69.9 percent allowance rate and the Art Unit 1600 designation help determine a prosecution approach for the case. These data points from Tech Center 2600 support planning for the patent process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18447437 | CELL MANAGEMENT SYSTEM AND CELL MANAGEMENT METHOD | Non-Final OA | Canon Kabushiki Kaisha |
| 18024548 | METHODS FOR ESTIMATING HETERGENEITY OF A TUMOUR BASED ON VALUES FOR TWO OR MORE GENOME MUTATION AND/OR GENE EXPRESSION RELATED PARAMETER, AS WELL AS CORRESPONDING DEVICES | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18369357 | METHOD OF AND SYSTEM FOR IDENTIFYING AND AMELIORATING BODY DEGRADATIONS | Non-Final OA | KPN INNOVATIONS, LLC. |
| 16552375 | Segmentation Of Video According To Narrative Theme | Final Rejection | Comcast Cable Communications, LLC |
| 17243481 | ELECTROCHEMICAL DETECTION OF BACTERIAL AND/OR FUNGAL INFECTIONS | Final Rejection | ROCHE MOLECULAR SYSTEMS, INC |
| 18188266 | MACHINE LEARNING PREDICTION OF INJECTION FREQUENCY IN PATIENTS WITH MACULAR EDEMA | Non-Final OA | HOFFMANN-LA ROCHE INC. |
| 18189842 | SEQUENCE-TO-SEQUENCE BASE CALLING | Non-Final OA | Illumina, Inc. |
| 18160678 | PREDICTING A RECOMMENDED THERAPY FROM GUT COMPOSITIONAL DATA | Non-Final OA | Institute for Systems Biology |
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | Final Rejection | National Institutes of Biomedical Innovation, Health and Nutrition |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy